JP2013539786A - 置換ベンズアミドおよびその使用法 - Google Patents

置換ベンズアミドおよびその使用法 Download PDF

Info

Publication number
JP2013539786A
JP2013539786A JP2013533917A JP2013533917A JP2013539786A JP 2013539786 A JP2013539786 A JP 2013539786A JP 2013533917 A JP2013533917 A JP 2013533917A JP 2013533917 A JP2013533917 A JP 2013533917A JP 2013539786 A JP2013539786 A JP 2013539786A
Authority
JP
Japan
Prior art keywords
methyl
compound
optionally substituted
pyridinyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013533917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539786A5 (https=
Inventor
ジアッチア アマート
ライ エドウィン
ラゾレノーバ オルガ
チャン デニス
パトリック ハイ マイケル
ボネット ミュリエル
サン コニー
タビビアザール レイ
ワイ エン ポ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Aravive Biologics Inc
Original Assignee
Auckland Uniservices Ltd
Ruga Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd, Ruga Corp filed Critical Auckland Uniservices Ltd
Publication of JP2013539786A publication Critical patent/JP2013539786A/ja
Publication of JP2013539786A5 publication Critical patent/JP2013539786A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2013533917A 2010-10-11 2011-10-10 置換ベンズアミドおよびその使用法 Pending JP2013539786A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39195810P 2010-10-11 2010-10-11
US61/391,958 2010-10-11
US201161434976P 2011-01-21 2011-01-21
US61/434,976 2011-01-21
US201161475549P 2011-04-14 2011-04-14
US61/475,549 2011-04-14
PCT/US2011/055624 WO2012051117A2 (en) 2010-10-11 2011-10-10 Substituted benzamides and their uses

Publications (2)

Publication Number Publication Date
JP2013539786A true JP2013539786A (ja) 2013-10-28
JP2013539786A5 JP2013539786A5 (https=) 2014-11-27

Family

ID=45938912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533917A Pending JP2013539786A (ja) 2010-10-11 2011-10-10 置換ベンズアミドおよびその使用法

Country Status (10)

Country Link
US (2) US9085570B2 (https=)
EP (1) EP2627324A4 (https=)
JP (1) JP2013539786A (https=)
KR (1) KR20140027907A (https=)
CN (1) CN103327972A (https=)
AU (1) AU2011313853A1 (https=)
BR (1) BR112013008898A2 (https=)
CA (1) CA2814503A1 (https=)
WO (1) WO2012051117A2 (https=)
ZA (1) ZA201302854B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158691A1 (en) * 2011-05-19 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Anti-proliferative compounds and methods for using the same
US9296732B2 (en) 2012-04-12 2016-03-29 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）のモジュレーター
JP2005528459A (ja) * 2002-06-06 2005-09-22 アベンティス、ファルマ、ドイチュラント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング ＧＰＩｂ−ｖＷＦ相互作用の阻害薬、それらの製造および使用
JP2008518999A (ja) * 2004-11-08 2008-06-05 エヴォテック・アクチエンゲゼルシャフト １１β−ＨＳＤ１阻害剤
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
WO2010078408A1 (en) * 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Heteroaryl compounds useful as raf kinase inhibitors
WO2011011514A1 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl benzamides, compositions and methods of use
WO2011039353A1 (en) * 2009-10-02 2011-04-07 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US7235558B2 (en) * 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
AU2003900207A0 (en) * 2003-01-17 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. New compounds
TW200505446A (en) 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
US20080293711A1 (en) 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
WO2009097113A2 (en) 2008-01-28 2009-08-06 New York University Oxazole and thiazole compounds as b-catenin modulators and uses thereof
HRP20170357T1 (hr) 2008-10-10 2017-05-05 Vm Discovery, Inc. Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti
WO2012100223A1 (en) * 2011-01-21 2012-07-26 John Irwin Synthetic lethal targeting of glucose transport
WO2012158691A1 (en) * 2011-05-19 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Anti-proliferative compounds and methods for using the same
US9296732B2 (en) * 2012-04-12 2016-03-29 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）のモジュレーター
JP2005528459A (ja) * 2002-06-06 2005-09-22 アベンティス、ファルマ、ドイチュラント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング ＧＰＩｂ−ｖＷＦ相互作用の阻害薬、それらの製造および使用
JP2008518999A (ja) * 2004-11-08 2008-06-05 エヴォテック・アクチエンゲゼルシャフト １１β−ＨＳＤ１阻害剤
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
WO2010078408A1 (en) * 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Heteroaryl compounds useful as raf kinase inhibitors
WO2011011514A1 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl benzamides, compositions and methods of use
WO2011039353A1 (en) * 2009-10-02 2011-04-07 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers

Also Published As

Publication number Publication date
BR112013008898A2 (pt) 2016-06-28
ZA201302854B (en) 2014-07-25
US9085570B2 (en) 2015-07-21
AU2011313853A1 (en) 2013-05-02
WO2012051117A2 (en) 2012-04-19
CA2814503A1 (en) 2012-04-19
WO2012051117A3 (en) 2012-06-14
US20150329503A1 (en) 2015-11-19
EP2627324A4 (en) 2014-05-07
US20140024649A1 (en) 2014-01-23
KR20140027907A (ko) 2014-03-07
CN103327972A (zh) 2013-09-25
EP2627324A2 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
JP2013539786A (ja) 置換ベンズアミドおよびその使用法
KR101458006B1 (ko) Ttx-s 차단제로서의 아릴아미드 유도체
KR102067235B1 (ko) Ttx-s 차단제로서 아미드 유도체
JP2015516393A (ja) 置換ベンズアミドおよびその使用法
BRPI0714663A2 (pt) composto e composiÇÕes como moduladores da via hedgehog
MX2007000265A (es) Compuestos utiles para inhibir chk1.
JP2010524937A (ja) Ｓｍｏアンタゴニストであるトリアゾール誘導体
CA2887887C (en) Pyrazolopyridine derivatives as ttx-s blockers
TW202021956A (zh) 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
JP2025504916A (ja) 化合物及び使用方法
JP5789603B2 (ja) ヘテロアリールベンズアミド、組成物および使用の方法
EA023064B1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
WO2017152032A1 (en) Novel oxazole and thiazole compounds as β-catenin modulators and uses thereof
HK1171190B (en) Heteroaryl benzamides, compositions and methods of use
HK1188600B (en) Arylamide derivatives as ttx-s blockers
HK1188600A (en) Arylamide derivatives as ttx-s blockers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161025